This Month's Tiny Gems - September 2015
Anavex Life Sciences Corp. (AVXL)
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat central nervous system diseases and various types of cancer. The company's lead drug candidate, ANAVEX 2-73, is currently being studied in a phase IIa clinical trial for the treatment of Alzheimer's disease. In preclinical studies, Anavex's groundbreaking candidate demonstrated the potential to halt and reverse the course of this life-threatening condition. Additionally, the company was recently awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research to begin development of ANAVEX 2-73 for the treatment of Parkinson's disease.
Digital Power Corp. (DPW)
Digital Power designs, develops, manufactures and sells high-grade customized and off-the-shelf power system solutions for the most demanding applications in the medical, military, telecom and industrial markets. In July, the company unveiled its newest family of products, which features a series of advanced, high-efficiency capacitor chargers specially designed for powering laser systems in medical and industrial applications. Through this release, DPW demonstrated its ongoing commitment to innovation in the development of best-in-class power solutions for a broad range of industries and challenging environments.
Erin Energy Corp. (ERN)
Erin Energy is an independent oil and gas exploration and production company focused on energy resources in sub-Saharan Africa. The company's asset portfolio includes nine licenses across four countries covering an area of approximately 16,600 square miles, including current production and exploration projects offshore Nigeria, as well as exploration licenses offshore Ghana and the Gambia and both offshore and onshore Kenya. By expertly managing its investments and on-going operations, Erin Energy is able to combat current market conditions by limiting capital exposure while maintaining economic efficiency in its operations and maximizing investment value.
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas Biopharma Holdings is a clinical-stage biopharmaceutical company focused on the development of safe and effective broad spectrum antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections. The company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleate to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally available. Matinas's lead drug candidate, MAT2203, is an orally administered, encochleated formulation of amphotericin B, an antifungal drug currently used intravenously to treat a variety of fungal infections.